Can a generic match the original heart failure drug?

NCT ID NCT07746908

Completed Knowledge-focused Sponsor: Center for Bioequivalence Studies and Clinical Research Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This trial checks whether a generic version of the heart failure drug sacubitril/valsartan (called Valsatril) is absorbed by the body the same way as the brand-name drug Entresto. Sixty healthy adults will take a single dose of each tablet under fasting conditions, with a break in between. Researchers will measure drug levels in the blood to see if the two versions are bioequivalent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/Valsartan (as Valsatril or Entresto tablets)
What this could lead to: If the generic matches the brand-name drug, it could offer a more affordable treatment option for heart failure.
What could go wrong: This is an early-phase study in healthy volunteers, so results may not reflect real-world use in patients. The generic must prove it is absorbed the same way.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Center for Bioequivalence Studies and Clinical Research (CBSCR) , ICCBS, University of Karachi

Karachi, Sindh, 75270, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.